Since both NF-κB pathway inhibition and NRF2 activation failed to downregulate MYB gene expression in T-ALL cells, this suggests that the two OT drugs act through alternative mechanisms to inhibit MYB activity. This evidence concerns the gene NFKB1 and acute lymphoblastic leukemia.